Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, other demographic and clinical characteristics were comparable between study subjects treated with monthly and weekly oral BPs.Clinical characteristics of female patients with rheumatoid arthritis receiving oral bisphosphonatesMonthly BP(n = 158)Weekly BP(n = 238) p valueTotal subjects(n = 396)Age, years, mean ± SD66.5 ± 10.565.6 ± 11.90.41665.9 ± 11.3Disease duration, months, median (IQR)42 (12.5 to 82)35 (18 to 86)0.739 (18 to 84)Seropositive RA, n (%)131 (82.9)193 (81.1)0.646324 (81.8)DAS28-ESR, mean ± SD3.53 ± 1.673.84 ± 1.670.0893.72 ± 1.68Concurrent medications Methotrexate, n (%)93 (58.9)149 (62.6)0.454242 (61.1) Sulfasalazine, n (%)18 (11.4)37 (15.5)0.24255 (13.9) Hydroxychloroquine, n (%)86 (54.4)121 (50.8)0.484207 (52.3) Leflunomide, n (%)29 (18.4)49 (20.6)0.58479 (19.7) Glucocorticoid, n (%)138 (87.9)206 (86.6)0.697344 (86.9) Glucocorticoid dose, mg, median (IQR)7.5 (5 to 10)7.5 (5 to 10)0.6317.5 (5 to 10) Calcium/vitamin D, n (%)32 (20.3)42 (17.6)0.51474 (18.7)Previous history of fracture, n (%)11 (7)18 (7.6)0.82229 (7.3)Baseline DEXA, n (%)152 (96.2)203 (85.3)<0.001355 (89.6)BMD (T score) Spine, mean ± SD−1.8 ± 1.4−1.7 ± 1.40.629−1.7 ± 1.4 Femoral neck, mean ± SD−1.5 ± 1.1−1.4 ± 1.10.273−1.5 ± 1.1 Total hip, mean ± SD− 1.3 ± 1.1− 1.3 ± 1.10.595−1.3 ± 1.1Reimbursement for BPs108 (68.4%)146 (61.3%)0.154254 (64.1%)BMI, mean ± SD22.4 ± 2.822.2 ± 3.20.43522.3 ± 3Comorbidity Type 2 DM, n (%)19 (12)16 (6.7)0.06935 (8.8) HTN, n (%)42 (26.6)56 (23.5)0.34298 (24.7) RA rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, BMD bone mineral density, BPs bisphosphonates, BMI body mass index, DM diabetes mellitus, HTN hypertension

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

To ensure correct identification of BP initiation and sufficient data for estimation of adherence, all patients were required to have medical record for 12 months preceding and following their index date [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis

Study design awaiting verification · BMC Musculoskeletal Disorders · 2017

Original publication title

Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis

Ji-Heh Park; Eun-Kyoung Park; Dong-Wan Koo; Shinwon Lee; Sun-Hee Lee; Geun-Tae Kim; Seung-Geun Lee

© The Author(s). 2017

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Compliance and persistence with oral BPs in RA patients were suboptimal in real practice, thereby limiting the efficacy of osteoporosis treatment. Extending the dosing interval of BPs may improve medication adherence in RA patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Poor adherence with oral bisphosphonates (BPs) can mitigate their therapeutic benefit for osteoporosis and is a significant clinical burden. Most previous studies regarding adherence with oral BPs have focused on postmenopausal osteoporosis, but little attention has been given to patients with rheumatoid arthritis (RA). Thus, we investigated compliance and persistence with oral BPs in the treatment of osteoporosis and analyzed risk factors for poor adherence in female patients with (RA) in real setting.

Source: Background

Abstract: What methods does the paper describe?

This is a retrospective longitudinal study including 396 female patients with RA in whom oral BPs were newly initiated from Aug 2004 to Aug 2014 at a university rheumatology center in South Korea. Compliance was quantified using the 1-year medication possession ratio (MPR), while persistence was defined as duration from the initiation to the end of BPs therapy without interruption exceeding 56 days. Seropositve RA was defined as having a positive test result for the presence of either rheumatoid factor or anti-cyclic citrullinated peptide antibody.

Source: Methods

Abstract: Results

Of 396 RA patients, 221 (55.8%) were prescribed risedronate 35 mg weekly; 17 (4.3%) received alendronate 70 mg weekly; and 158 (39.9%) received ibandronate 150 mg monthly. The 1-year MPR was 70.1% and the proportion of RA patients with the 1-year MPR ≥ 0.8 was 60.1%. A total of 274 (69.2%) patients discontinued oral BPs during the study period and persistence with BPs was 63.3% at 1 year, 50.7% at 2 years and 33.3% at 3 years. The most common cause of non-persistence was adverse events (47.5%), followed by poor health literacy (40.5%) and cost (12%).

Both compliance and persistence with monthly oral BPs were significantly lower than those with weekly regimens (OR: 2.48, 95% CI: 1.59 to 3.89, P < 0.001 and HR: 2.19, 95% CI: 1.69 to 2.83, P < 0.001, respectively). Additionally, patients with seropositive RA showed better compliance and persistence with BPs compared with their seronegative counterparts.

Source: Results

Abstract: Conclusions

Compliance and persistence with oral BPs in RA patients were suboptimal in real practice, thereby limiting the efficacy of osteoporosis treatment. Extending the dosing interval of BPs may improve medication adherence in RA patients.

Source: Conclusions
Authors’ abstract

Background

Poor adherence with oral bisphosphonates (BPs) can mitigate their therapeutic benefit for osteoporosis and is a significant clinical burden. Most previous studies regarding adherence with oral BPs have focused on postmenopausal osteoporosis, but little attention has been given to patients with rheumatoid arthritis (RA). Thus, we investigated compliance and persistence with oral BPs in the treatment of osteoporosis and analyzed risk factors for poor adherence in female patients with (RA) in real setting.

Methods

This is a retrospective longitudinal study including 396 female patients with RA in whom oral BPs were newly initiated from Aug 2004 to Aug 2014 at a university rheumatology center in South Korea. Compliance was quantified using the 1-year medication possession ratio (MPR), while persistence was defined as duration from the initiation to the end of BPs therapy without interruption exceeding 56 days. Seropositve RA was defined as having a positive test result for the presence of either rheumatoid factor or anti-cyclic citrullinated peptide antibody.

Results

Of 396 RA patients, 221 (55.8%) were prescribed risedronate 35 mg weekly; 17 (4.3%) received alendronate 70 mg weekly; and 158 (39.9%) received ibandronate 150 mg monthly. The 1-year MPR was 70.1% and the proportion of RA patients with the 1-year MPR ≥ 0.8 was 60.1%. A total of 274 (69.2%) patients discontinued oral BPs during the study period and persistence with BPs was 63.3% at 1 year, 50.7% at 2 years and 33.3% at 3 years. The most common cause of non-persistence was adverse events (47.5%), followed by poor health literacy (40.5%) and cost (12%).

Both compliance and persistence with monthly oral BPs were significantly lower than those with weekly regimens (OR: 2.48, 95% CI: 1.59 to 3.89, P < 0.001 and HR: 2.19, 95% CI: 1.69 to 2.83, P < 0.001, respectively). Additionally, patients with seropositive RA showed better compliance and persistence with BPs compared with their seronegative counterparts.

Conclusions

Compliance and persistence with oral BPs in RA patients were suboptimal in real practice, thereby limiting the efficacy of osteoporosis treatment. Extending the dosing interval of BPs may improve medication adherence in RA patients.

Publication and source details

Original title: Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis

Ji-Heh Park; Eun-Kyoung Park; Dong-Wan Koo; Shinwon Lee; Sun-Hee Lee; Geun-Tae Kim; Seung-Geun Lee

BMC Musculoskeletal Disorders · 2017

© The Author(s). 2017https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.This work was supported by clinical research grant from Pusan National University Hospital 2016

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:43:44.250683+00:00

DOI: 10.1186/s12891-017-1514-4 · PMC5387221